MYLAN 2036 MYLAN 2036 (Topiramate (sprinkle) 25 mg)
Pill imprint MYLAN 2036 MYLAN 2036 has been identified as Topiramate (sprinkle) 25 mg.
Topiramate is used in the treatment of obesity; migraine prevention; fibromyalgia; vulvodynia; bulimia (and more), and belongs to the drug class carbonic anhydrase inhibitor anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Topiramate 25 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- MYLAN 2036 MYLAN 2036
- Strength:
- 25 mg
- Color:
- Pink
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- Carbonic anhydrase inhibitor anticonvulsants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Mylan Pharmaceuticals Inc.
More about topiramate
Consumer resources
- Topiramate
- Topiramate extended-release capsules
- Topiramate sprinkle capsules
- Topiramate (Advanced Reading)
- Other brands: Topamax, Trokendi XR, Topiragen, Topamax Sprinkle, More (1) »
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
